These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9380298)

  • 21. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
    Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
    Cheng ZQ; Yin W; Fan JY; Ma TJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):306-9. PubMed ID: 12905641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The distal radial fracture in elderly women and the bone mineral density of the lumbar spine and hip.
    Hegeman JH; Oskam J; van der Palen J; Ten Duis HJ; Vierhout PA
    J Hand Surg Br; 2004 Oct; 29(5):473-6. PubMed ID: 15336753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of bone mineral density (BMD) with quantitative computed tomography (QCT) in postmenopausal osteoporosis: effect of estrogen.
    Zgliczyński S; Szulc P; Słowińska-Srzednicka J; Stopińska-Głuszak U; Misiorowski W; Jeske W; Snochowska H; Wagiel K; Walecki J
    Endokrynol Pol; 1992; 43(3):350-7. PubMed ID: 1345576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bone density screening in females in climacteric].
    Heytmanek G
    Wien Med Wochenschr; 1992; 142(5-6):130-2. PubMed ID: 1615683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [What is reliable in the treatment of osteoporosis in menopausal women?].
    Ziegler R
    Internist (Berl); 1993 Jan; 34(1):18-24. PubMed ID: 8440570
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug therapy of osteoporosis].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2003 Aug; 123(16):2263-4. PubMed ID: 14508549
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevalence of postmenopausal osteoporosis in Italy and validation of decision rules for referring women for bone densitometry.
    D'Amelio P; Spertino E; Martino F; Isaia GC
    Calcif Tissue Int; 2013 May; 92(5):437-43. PubMed ID: 23334353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Menostar: a low-dose estrogen patch for osteoporosis.
    Obstet Gynecol; 2005 Feb; 105(2):432-3. PubMed ID: 15684177
    [No Abstract]   [Full Text] [Related]  

  • 31. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
    Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
    Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond bone mineral density: several factors define bone health.
    Ruhl C
    Nurs Womens Health; 2008 Jun; 12(3):249-51. PubMed ID: 18557856
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of osteoporosis with estrogen].
    Mizunuma H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():397-403. PubMed ID: 15035159
    [No Abstract]   [Full Text] [Related]  

  • 34. Summaries for patients. Bone loss after stopping estrogen or alendronate therapy.
    Ann Intern Med; 2002 Dec; 137(11):I31. PubMed ID: 12459003
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term bone mass evaluation of mandible and lumbar spine in a group of women receiving hormone replacement therapy.
    Jacobs R; Ghyselen J; Koninckx P; van Steenberghe D
    Eur J Oral Sci; 1996 Feb; 104(1):10-16. PubMed ID: 8653490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medroxyprogesterone and bone mineral density response to oestrogen.
    Kanis JA
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):297-8. PubMed ID: 8729525
    [No Abstract]   [Full Text] [Related]  

  • 37. Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons.
    Deal CL
    Curr Rheumatol Rep; 2001 Jun; 3(3):233-9. PubMed ID: 11352792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do estrogens improve bone mass in osteoporotic women over ten years of menopause.
    Szejnfeld VL; Souen JS; Baracat EC; Atra E; de Lima GR
    Sao Paulo Med J; 1994; 112(1):517-21. PubMed ID: 7871318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Practical procedure in osteoporosis fracture. Interview by Dr. Till Uwe Keil].
    Semler J
    Fortschr Med; 1993 Jun; 111(16):44-5. PubMed ID: 8330829
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women.
    Sugimoto AK; Hodsman AB; Nisker JA
    Fertil Steril; 1993 Oct; 60(4):672-4. PubMed ID: 8405523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.